1 |
Selected radiotracers as imaging tools for the investigation of nano-sized delivery systems / Vusani MandiwanaMandiwana, Vusani January 2014 (has links)
Developing nanoparticulate delivery systems that will allow easy movement and localisation of a drug to the target tissue and provide more controlled release of the drug in vivo is a challenge for researchers in nanomedicine. The aim of this study was to evaluate the biodistribution of two nano-delivery systems namely, poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles containing samarium-153 oxide ([153Sm]Sm2O3) as radiotracer and solid lipid nanoparticles (SLNs) containing technetium-99m-methylene diphosphonate (99mTc-MDP), after oral and intravenous administration to rats to prove that orally administered nanoparticles indeed alter the biodistribution of a drug as compared to the drug on its own.
Stable samarium-152 oxide ([152Sm]Sm2O3) was encapsulated in polymeric PLGA nanoparticles. These were then activated in a nuclear reactor to produce radioactive [153Sm]Sm2O3 loaded-PLGA nanoparticles. Both the stable nanoparticles as well as the fully decayed activated nanoparticles, were characterized for size, Zeta potential and morphology using dynamic light scattering and scanning electron microscopy (SEM) or transmission electron microscopy (TEM), respectively. SLNs were a form of delivery system which was used to encapsulate the radiotracer, 99mTc-MDP. 99mTc-MDP SLNs were characterized before and after encapsulation for size and Zeta potential. Both nanoparticle compounds were orally and intravenously (IV) administered to rats in order to trace their uptake and biodistribution through imaging and ex vivo biodistribution studies.
The PLGA nanoparticles containing [153Sm]Sm2O3 were spherical in morphology and smaller than 500 nm, therefore meeting the objective of producing radiolabelled nanoparticles smaller than 500 nm. Various parameters were optimized to obtain an average particle size ranging between 250 and 300 nm, with an average polydispersity index (PDI) ≤ 0.3 after spray drying. The particles had a Zeta potential ranging between 5 and 20 mV. The Sm2O3-PLGA nanoparticles had an average size of 281 ± 6.3 nm and a PDI average of 0.22. The orally administered [153Sm]Sm2O3-PLGA nanoparticles were deposited in various organs which includes bone with a total of 0.3% of the Injected Dose (ID) per gram vs the control of [153Sm]Sm2O3which showed no uptake in any organs except the GI-tract. The IV injected [153Sm]Sm2O3-PLGA nanoparticles exhibit the highest localisation of nanoparticles in the spleen (8.63%ID/g) and liver (3.07%ID/g).
The 99mTc-MDP-labelled SLN were spherical and smaller than 500 nm. Optimization of the MDP-loaded SLN emulsions yielded a slightly higher PDI of ≥0.5 and a size range between 150 and 450 nm. The Zeta potential was between -30 and -2 mV. The MDP-loaded SLN had an average size of 256 ± 5.27 and an average PDI of 0.245.The orally administered 99mTc-MDP SLN had the highest localisation of nanoparticles in the kidneys (8.50%ID/g) and stomach (8.04%ID/g) while the control, 99mTc-MDP had no uptake in any organs except the GI-tract. The IV injected 99mTc-MDP SLN also exhibited a high localisation of particles in the kidneys (3.87%ID/g) followed by bone (2.66%ID/g). Both the IV and oral 99mTc-MDP SLN reported significantly low deposition values in the heart, liver and spleen.
Based on the imaging and the biodistribution studies, it can be concluded that there was a significant transfer of the orally administrated radiolabelled nanoparticles from the stomach to other organs vs the controls. Furthermore, this biodistribution of the nano carriers warrants surface modification and optimisation of the nanoparticles to avoid higher particle localisation in the stomach. / MSc (Pharmaceutics), North-West University, Potchefstroom Campus, 2014
|
2 |
Radio-labelling as a tool to investigate the absorption and bio-distribution of selected antimalarial drugs / Abraham Johannes SwanepoelSwanepoel, Abraham Johannes January 2014 (has links)
Previous studies have shown that the formulation of an active pharmaceutical ingredient (API) entrapped in the Pheroid® (Pheroid for simplification) delivery system enhances absorption of the API, suppresses its metabolism, and may contribute to an increase in the quantity of the API present at the site of action. Higher drug levels at the active site should particularly increase the effectiveness of a drug with a narrow therapeutic index and reduce the incidence of the resistance that may otherwise arise if the sub-therapeutic levels of the API are in contact with the site of interest.
Two approaches were followed in this study. First, the radioactive tracer molecule 99mTechnetium methylene diphosphonate (99mTc MDP) was used. Intravenously injected 99mTc MDP is an extremely effective bone-seeking radiopharmaceutical used in the diagnosis of bone disorders such as bone metastases in patients. However, if entrapped inside a Pheroid vesicle, it will locate to that site, usually an organ, where the Pheroid vesicles may tend to accumulate. Experiments conducted with 99mTc MDP alone or with Pheroid will therefore establish how efficiently Pheroid vesicles localize and will also indicate the preferred site of localization inside a body. The process would involve the oral administration of 99mTc MDP either alone or with Pheroid, involving an animal model. It would also involve tracking localization to particular organs, blood or other sites. The second approach requires the use of chloroquine (CQ) labeled with carbon-14 (14C-CQ,) to compare absorption of the drug both with and without the Pheroid system.
The intention was to compare oral absorption and bio-distribution of 14C-CQ administered either alone or entrapped in the Pheroid system. It was also possible to establish whether the Pheroid affects the biological half-lives of the CQ and residence times of CQ in the different organs of the body.
Absorption of free 99mTc MDP (orally adminsistered) through the intestinal tract is negligible but it was anticipated that increased absorption will be observed when 99mTc MDP was
entrapped in the Pheroid system. In the 99mTc MDP study, different routes of administration of 99mTc MDP, as well as 99mTc MDP entrapped and not entrapped in the Pheroid system, were investigated. The Sprague Dawley rat was used as animal model. Rats were divided into three groups of four rats each for the first part of the study. In the first group, only 99mTc MDP was injected intravenously in order to establish natural distribution of the 99mTc MDP. For the second group, 99mTc MDP was administered orally in order to establish whether there was any absorption through the intestinal tract. In the third group, the 99mTc MDP was entrapped in Pheroid vesicles and this formulation was administered orally in order to establish whether the Pheroid system enhanced oral absorption. The animals were sacrificed four hours after administration and organs were harvested and were counted for radioactivity to determine the percentage of injected/administrated dose in each organ.
After oral administration, the Pheroid system was found to have facilitated absorption of 99mTc MDP through the intestinal tract into the blood. 99mTc MDP concentrations in the femur, although lower, were still comparable with that observed after intravenous administration of 99mTc MDP in the absence of Pheroid. Thus, overall, excellent absorption of the Pheroid entrapped 99mTc MDP through the intestinal tract was seen in contrast to little or zero absorption of the compound in the reference formulations. The half-life of the radio-labelled compound in the blood was prolonged after oral administration owing to the Pheroid.
To investigate the bio-distribution of radioactive chloroquine (14C-CQ) Sprague Dawley rats were divided into two groups of four rats each. In the first group, 14C-CQ in deionised (DI) water was administered orally, and in the second group 14C-CQ entrapped in Pheroid vesicles was administered, also orally. The animals were sacrificed one, two and four hours after administration and subjected to comprehensive macroscopic inspection. All the organs were harvested and radioactivity was determined with liquid scintillation after applicable sample preparation. The Pheroid system produced much higher organ and blood
concentrations of 14C-CQ and enhanced residence times within the organs and blood in comparison with that of 14C-CQ administered alone.
Commercial applications of these results are possible, as a number of radiopharmaceutical products can presently be administered only intravenously. The added potential of these new Pheroid formulations could be of significance in the treatment of malaria, as chloroquine is inexpensive and widely available. Another point of interest is that the use of these formulations may enable micromolar drug concentrations to be achieved using drug dosage regimes that usually produce only nanomolar levels. However, safety aspects would have to be carefully monitored. / PhD (Pharmaceutics), North-West University, Potchefstroom Campus, 2015
|
3 |
Selected radiotracers as imaging tools for the investigation of nano-sized delivery systems / Vusani MandiwanaMandiwana, Vusani January 2014 (has links)
Developing nanoparticulate delivery systems that will allow easy movement and localisation of a drug to the target tissue and provide more controlled release of the drug in vivo is a challenge for researchers in nanomedicine. The aim of this study was to evaluate the biodistribution of two nano-delivery systems namely, poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles containing samarium-153 oxide ([153Sm]Sm2O3) as radiotracer and solid lipid nanoparticles (SLNs) containing technetium-99m-methylene diphosphonate (99mTc-MDP), after oral and intravenous administration to rats to prove that orally administered nanoparticles indeed alter the biodistribution of a drug as compared to the drug on its own.
Stable samarium-152 oxide ([152Sm]Sm2O3) was encapsulated in polymeric PLGA nanoparticles. These were then activated in a nuclear reactor to produce radioactive [153Sm]Sm2O3 loaded-PLGA nanoparticles. Both the stable nanoparticles as well as the fully decayed activated nanoparticles, were characterized for size, Zeta potential and morphology using dynamic light scattering and scanning electron microscopy (SEM) or transmission electron microscopy (TEM), respectively. SLNs were a form of delivery system which was used to encapsulate the radiotracer, 99mTc-MDP. 99mTc-MDP SLNs were characterized before and after encapsulation for size and Zeta potential. Both nanoparticle compounds were orally and intravenously (IV) administered to rats in order to trace their uptake and biodistribution through imaging and ex vivo biodistribution studies.
The PLGA nanoparticles containing [153Sm]Sm2O3 were spherical in morphology and smaller than 500 nm, therefore meeting the objective of producing radiolabelled nanoparticles smaller than 500 nm. Various parameters were optimized to obtain an average particle size ranging between 250 and 300 nm, with an average polydispersity index (PDI) ≤ 0.3 after spray drying. The particles had a Zeta potential ranging between 5 and 20 mV. The Sm2O3-PLGA nanoparticles had an average size of 281 ± 6.3 nm and a PDI average of 0.22. The orally administered [153Sm]Sm2O3-PLGA nanoparticles were deposited in various organs which includes bone with a total of 0.3% of the Injected Dose (ID) per gram vs the control of [153Sm]Sm2O3which showed no uptake in any organs except the GI-tract. The IV injected [153Sm]Sm2O3-PLGA nanoparticles exhibit the highest localisation of nanoparticles in the spleen (8.63%ID/g) and liver (3.07%ID/g).
The 99mTc-MDP-labelled SLN were spherical and smaller than 500 nm. Optimization of the MDP-loaded SLN emulsions yielded a slightly higher PDI of ≥0.5 and a size range between 150 and 450 nm. The Zeta potential was between -30 and -2 mV. The MDP-loaded SLN had an average size of 256 ± 5.27 and an average PDI of 0.245.The orally administered 99mTc-MDP SLN had the highest localisation of nanoparticles in the kidneys (8.50%ID/g) and stomach (8.04%ID/g) while the control, 99mTc-MDP had no uptake in any organs except the GI-tract. The IV injected 99mTc-MDP SLN also exhibited a high localisation of particles in the kidneys (3.87%ID/g) followed by bone (2.66%ID/g). Both the IV and oral 99mTc-MDP SLN reported significantly low deposition values in the heart, liver and spleen.
Based on the imaging and the biodistribution studies, it can be concluded that there was a significant transfer of the orally administrated radiolabelled nanoparticles from the stomach to other organs vs the controls. Furthermore, this biodistribution of the nano carriers warrants surface modification and optimisation of the nanoparticles to avoid higher particle localisation in the stomach. / MSc (Pharmaceutics), North-West University, Potchefstroom Campus, 2014
|
4 |
Radio-labelling as a tool to investigate the absorption and bio-distribution of selected antimalarial drugs / Abraham Johannes SwanepoelSwanepoel, Abraham Johannes January 2014 (has links)
Previous studies have shown that the formulation of an active pharmaceutical ingredient (API) entrapped in the Pheroid® (Pheroid for simplification) delivery system enhances absorption of the API, suppresses its metabolism, and may contribute to an increase in the quantity of the API present at the site of action. Higher drug levels at the active site should particularly increase the effectiveness of a drug with a narrow therapeutic index and reduce the incidence of the resistance that may otherwise arise if the sub-therapeutic levels of the API are in contact with the site of interest.
Two approaches were followed in this study. First, the radioactive tracer molecule 99mTechnetium methylene diphosphonate (99mTc MDP) was used. Intravenously injected 99mTc MDP is an extremely effective bone-seeking radiopharmaceutical used in the diagnosis of bone disorders such as bone metastases in patients. However, if entrapped inside a Pheroid vesicle, it will locate to that site, usually an organ, where the Pheroid vesicles may tend to accumulate. Experiments conducted with 99mTc MDP alone or with Pheroid will therefore establish how efficiently Pheroid vesicles localize and will also indicate the preferred site of localization inside a body. The process would involve the oral administration of 99mTc MDP either alone or with Pheroid, involving an animal model. It would also involve tracking localization to particular organs, blood or other sites. The second approach requires the use of chloroquine (CQ) labeled with carbon-14 (14C-CQ,) to compare absorption of the drug both with and without the Pheroid system.
The intention was to compare oral absorption and bio-distribution of 14C-CQ administered either alone or entrapped in the Pheroid system. It was also possible to establish whether the Pheroid affects the biological half-lives of the CQ and residence times of CQ in the different organs of the body.
Absorption of free 99mTc MDP (orally adminsistered) through the intestinal tract is negligible but it was anticipated that increased absorption will be observed when 99mTc MDP was
entrapped in the Pheroid system. In the 99mTc MDP study, different routes of administration of 99mTc MDP, as well as 99mTc MDP entrapped and not entrapped in the Pheroid system, were investigated. The Sprague Dawley rat was used as animal model. Rats were divided into three groups of four rats each for the first part of the study. In the first group, only 99mTc MDP was injected intravenously in order to establish natural distribution of the 99mTc MDP. For the second group, 99mTc MDP was administered orally in order to establish whether there was any absorption through the intestinal tract. In the third group, the 99mTc MDP was entrapped in Pheroid vesicles and this formulation was administered orally in order to establish whether the Pheroid system enhanced oral absorption. The animals were sacrificed four hours after administration and organs were harvested and were counted for radioactivity to determine the percentage of injected/administrated dose in each organ.
After oral administration, the Pheroid system was found to have facilitated absorption of 99mTc MDP through the intestinal tract into the blood. 99mTc MDP concentrations in the femur, although lower, were still comparable with that observed after intravenous administration of 99mTc MDP in the absence of Pheroid. Thus, overall, excellent absorption of the Pheroid entrapped 99mTc MDP through the intestinal tract was seen in contrast to little or zero absorption of the compound in the reference formulations. The half-life of the radio-labelled compound in the blood was prolonged after oral administration owing to the Pheroid.
To investigate the bio-distribution of radioactive chloroquine (14C-CQ) Sprague Dawley rats were divided into two groups of four rats each. In the first group, 14C-CQ in deionised (DI) water was administered orally, and in the second group 14C-CQ entrapped in Pheroid vesicles was administered, also orally. The animals were sacrificed one, two and four hours after administration and subjected to comprehensive macroscopic inspection. All the organs were harvested and radioactivity was determined with liquid scintillation after applicable sample preparation. The Pheroid system produced much higher organ and blood
concentrations of 14C-CQ and enhanced residence times within the organs and blood in comparison with that of 14C-CQ administered alone.
Commercial applications of these results are possible, as a number of radiopharmaceutical products can presently be administered only intravenously. The added potential of these new Pheroid formulations could be of significance in the treatment of malaria, as chloroquine is inexpensive and widely available. Another point of interest is that the use of these formulations may enable micromolar drug concentrations to be achieved using drug dosage regimes that usually produce only nanomolar levels. However, safety aspects would have to be carefully monitored. / PhD (Pharmaceutics), North-West University, Potchefstroom Campus, 2015
|
Page generated in 0.0211 seconds